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ABSTRAK
Tujuan: menilai efek potensial probiotik E. coli Nissle 1917 yang dapat membawa perbaikan dalam tatalaksana 
IBS refrakter pada populasi di Iran. Metode: pendekatan terkontrol plasebo tersamar ganda telah dipakai dalam 
uji klinis ini. Sebanyak 139 pasien yang dipastikan menderita IBS ikut serta dalam penelitian ini dan diberikan 
probiotik E.coliNissle 1917 selama 6 minggu. 11 butir pertanyaan dari Birmingham IBS Symptom Questionnaire 
telah dipakai untuk menilai perubahan gejala setiap 2 minggu. Hasil: enam puluh delapan (49%) subyek adalah laki-
laki. Usia rata-rata±SD peserta penelitian 38±13,3 tahun. Sebanyak 49 (35,3%) pasien dominan mengalami diare 
(diarrhea predominant). Skor total menunjukkan bahwa tidak ada perbedaan bermakna antara kelompok intervensi 
dibandingkan kelompok kontrol (-6,7±6,8 dibanding -6,7±6,5; p=0,95); tidak ada satu pun butir pertanyaan yang 
menunjukkan perubahan yang bermakna pada kedua kelompok. Setelah dilakukan stratifikasi pasien berdasarkan 
tipe IBS yang dideritanya, pasien yang dominan mengalami diare (diarrhea predominant) menunjukkan respons 
positif terhadap probiotik dan kualitas tidurnya membaik (p=0,05 dan 0,03 masing-masing untuk minggu ke-2 
dan ke-6). Pasien IBS dengan gejala dominan konstipasi (constipation-predominant) tidak menunjukkan respons 
terhadap probiotik; sedangkan pasien IBS dengan kombinasi diare dan kombinasi menunjukkan respons yang 
kurang baik terhadap probiotik dan butuh mengejan sebelum BAB dibandingkan kelompok plasebo (p= 0,03 dan 
0,02 masing-masing pada minggu ke-4 dan ke-6). Kesimpulan: terapi probiotik dengan E.coliNissle 1917 tidak 
dapat memperbaiki gejala pada pasien IBS tanpa kategori (non-categorized IBS). Meskipun demikian, ketika 
pasien IBS dikategori ulang menjadi subkelompok berdasarkan gejala utamanya, penilaian efektivitas probiotik 
atas beberapa butir terpisah dalam daftar gejala ternyata bermakna. Uji klinik prospektif disarankan dilakukan 
untuk memastikan temuan kami.
Kata kunci: probiotik Escherichia Coli Nissle 1917, sindroma iritasi usus (irritable bowel syndrome), uji 
klinik terkontrol tersamar ganda.
ABSTRACT
Aim: to evaluate potential improvement effect for probiotic E. coliNissle 1917 in the management of refractory 
IBS in an Iranian population. Methods: a double blind placebo controlled approach has been used in the current 
clinical trial. 139 confirmed IBS patients were included into the study, and were given probiotic E.coli Nissle 
1917 for 6 weeks. 11 items Birmingham IBS Symptom Questionnairehas been used for evaluation of changes in 
the symptoms every 2 weeks. Results: sixty eight subjects (49%) were males. Mean±SD age of the participants 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a complex 
condition, which is usually very hard to manage.1 
Effects of different therapeutic approaches have 
been modest or controversial compared to the 
placebo. Bulking agents and antispasmodics 
had either no or minimal beneficial effect in 
the management of IBS.2 Newer agents such 
as 5HT3 agonists3 and 5HT4 antagonists4 have 
minimal or controversial efficacy over placebo; 
moreover, both of the mentioned agent families 
are now either banned or restricted in general 
use for their serious health risk enhancement, 
especially in the cardiovascular system and 
ischemic colitis.5 So, the literature does not 
propose any effective option for the management 
of IBS, and this urges the scientific community 
to invest on finding effective treatment approach.
Several alternative therapies have been 
used for the management of IBS in different 
populations, which have revealed some prospects, 
though controversial.6 In search for pathogenesis 
of the illness, authors have reported changes in 
the microflora of the intestine, as a significant 
factor.7 Although controversy exists over the 
significance of these alterations of microflora, 
which can be a result or reason of IBS, there 
is overwhelming evidence suggestive of its 
casual role in the pathogenesis of IBS, with IBS 
getting inflamed after gastrointestinal infections.8 
Although these studies are highly indicative for 
the causative role of microbiota in the disease 
pathogenesis, more indisputable evidence will 
come out if improvements of gut microflora to 
the normal state results in the improvement of 
the illness.
Probiotics, consumable products that contain 
microbial content similar to that of a normal 
gutflora, have been used in several randomized 
controlled trials in hope to observe some 
therapeutic effects associated with them on the 
IBS;although the results were controversial 
with some studies highly suggestive of its 
beneficial effects9,10 and some thoroughly 
disappointing results.11,12 Different probiotics 
contain different microbial contents, so it seems 
logical to pretend different therapeutic effects for 
different products. Moreover, methodology of 
the probiotic administration in the IBS patients 
can also play a key role in the efficacy of the 
therapy in IBS patients. For the same reason, 
we conducted a double-blind placebo-controlled 
randomized trial to evaluate potential improving 
effect for probiotic E. coli Nissle 1917 in the 
management of refractory IBS in an Iranian 
population.
METHODS
Study Design and Diagnosis of the IBS
The study was designed using a double-
blind randomized placebo-controlled trial.
Participants were recruited from the outpatient 
Gastroenterology Clinic at Rasul-e-Akram 
Hospital in Tehran from the beginning of 
March 2010 to the end of October 2014. 
was 38±13.3 years. 49(35.3%) of the patients were diarrhea-predominant. The total scores showed no significant 
difference between the intervention vs. control group(-6.7±6.8 vs. -6.7±6.5, respectively; p=0.95); neither did any 
of the questionnaire items any significant alterations in the two groups. After stratification of patients based on 
their IBS type, diarrhea-predominant patients showed a positive response to the probiotic improving their sleep 
(p=0.05&0.03 at weeks 2&6, respectively). Patients with constipation-predominant IBS showed no response to 
the probiotic; while patients with diarrhea-constipation mixed IBS showed unfavorable response to the probiotic 
in the need for strain to pass a motion compared to the placebo (p=0.03&0.02 at weeks 4&6, respectively). 
Conclusion: probiotic therapy with E.coliNissle 1917 was not able to induce significant improvement in the symptoms 
of patients with non-categorized IBS. Nevertheless, when IBS patients were recategorized to subgroups according 
to their main symptoms, evaluation of the efficacy of the probiotic on some individual items in the symptom list 
reached the significance level. Prospective clinical trials are recommended to confirm our findings.
Key words: probiotic Escherichia Coli Nissle 1917, irritable bowel syndrome, double blind randomized 
controlled trial.
Vol 47 • Number 3 • July 2015            Efficacy of probiotic E. coli Nissle 1917 in patients with irritable bowel syndrome
203
Upon attendance to the clinic all the patients 
undergone full evaluations to exclude organic 
diseases based on the Kruis score13; and finally 
to define IBS according to the Rome II criteria14: 
Abdominal pain/discomfort for at least 12 weeks 
(not essentiallyconsecutive) within the last 12 
months, besides at least two of the following 
criteria: (1) relief after defecation; (2) onset 
associated with alterations in stools frequency 
and/or (3) onset associated with a change in stool 
appearance (form).
Randomization and Blinding Protocol
Randomization and blinding was carried 
out by a member of our research center who 
was not part of the study team. The boxes were 
coded as box nA or nB and sealed. Either of the 
two boxes marked as A or B contained probiotic 
Escherichia coli Nissle 1917. The labeled boxes 
were distributed to the patients by one of the 
authors. The key was stored and sealed beyond 
the reach of the investigators until the completion 
of the survey.
Inclusion and Exclusion Criteria
After diagnosis of IBS was confirmed 
at the Outpatient Clinic of Gastroenterology 
of Rasul-e-Akram Hospital, only those who 
had the following inclusion criteria were 
considered eligible to be included in the study: 
(1) participants should be between 20 to 50 years 
of age; (2) they should not have been under 
probiotic therapy during the last one month; 
(3) they should eagerly give informed consent 
for inclusion to the study. Patients would have 
be excluded if: (1) They were pregnant, or 
became pregnant during the study period; (2) 
if they had any significant abdominal surgery 
except for appendectomy or cholecystectomy; 
(3)if they had any other disorder with direct 
influence on the patients’ IBS; (4) any other 
active gastrointestinal disorder; (5) history of 
hypersensitivity to the cow-milk.
Study Participants
156 people were initially defined with the 
diagnosis of IBS, and entered the process for 
getting involved into the study. From these, 
17 patients have been excluded from the study 
because they did not meet the inclusion criteria. 
Finally 139 patients were left and included 
into the analysis.At the first follow up session, 
118 (84.9%) attended the clinic and filled 
the questionnaire; at the second follow up, 4 
weeks after the study, 108 (77.7%) of the initial 
participants returned back to the clinic, and at the 
third follow up, 105 (75.6%) attended the clinic 
and filled the questionnaire.
Intervention Protocol
Before participants were recruited into the 
final stage of the study, they were entered a 2 
week of run-in period through which they were 
asked to discontinue use of motility modifiers, 
antidepressants, opioids, narcotic analgesics and 
antispasmodic in cases, while use ofloperamide 
and prokinetic agents were allowed during the 
study. Also, no antibiotic agent should be used. 
After entering the study stage, patients who 
had been randomly assigned to receive either 
probiotics or placebo were given their agents 
for one month, and they were asked to fulfill an 
IBS-symptom-checklist at four time-points: (1) 
at the baseline; (2) at the second week after the 
trial starts; (3) at the 4th week after the start of 
the study; and (4) after the 6th week from the 
study commencement.
Ethics
All the study participants were asked to 
sign a consent form, all all of them were given 
full information about it before. The study has 
been approved by our local ethics committee in 
the Iran University of Medical Sciences, by the 
registration code ‘18904-30-03-91’.
Measuring Instrument
Birmingham IBS Symptom Questionnaire 
which consists of 11 symptoms related to IBS 
was used for evaluations. Each item consists of 5 
answers in a scale of 1 to 5 which would be rated 
by the patients after appropriate description, with 
higher scores indicative of higher intensity. The 
overall Birmingham IBS Symptom Questionnaire 
score was calculated summing scores of all the 
11 itemsfor each time-point. The changes in the 
overall scores were presented as mean± standard 
deviation (SD).
IBS Subtypes Categorization
IBS patients were categorized into three 
subgroups based on their main gastrointestinal 
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symptoms. Diarrhea-predominant, constipation-
predominant, and diarrhea-constipation mixed 
IBS were used to label IBS patients whose 
main symptoms were diarrhea, constipation or 
a mixture of them, respectively.
Other Defnitions
Body mass index (BMI) was defined as 
weight (Kg)/height (m)*height (m). BMI was 
defined as low-normal when it was equal or lower 
than 25 Kg/m2. It was defined as high, when it 
was over 25 Kg/m2. Categorizing response to 
treatment, we defined an improvement in each 
item, when the item score decreased from its 
baseline score, and no improvement when it 
either increased or changed not at all.
Statistical Analysis
Software SPSS version 17.0 (SPSS Inc, 
Chicago, Il, USA) has been used for analyses. 
Chi square test was used for analyzing categorical 
data. Student’s t test was used when comparing 
changes in questionnaire scores before and 
after the intervention. One-way ANOVA has 
been used for comparing continuous variables 
between the three IBS subtypes, and Tukey’s 
test was used for multiple comparisons, p value 
≤0.05 was considered significant.
RESULTS
Demographics
Overall 139 patients entered into the study 
and filled the questionnaire at the pre-treatment 
stage. 68 (48.9%) of the participants were 
males and 71 (51.1%) were females. Mean±SD 
age of the participants was 38±13.3 years. 
Mean weight was 69.3±13.9 kgs, mean height, 
168.8±9.4 cms and mean BMI was 24.2±3.9 
m/kg2. Forty-nine (35.3%) of the patients were 
diarrhea-predominant, while 55 (39.6%) were 
constipation predominant (5 missing data). The 
baseline characteristics were comparable between 
the patients in the two groups of the study.
Overall Analysis
At first, we analyzed potential changes in 
each of the 11 items of IBS symptomatology 
from the Birmingham questionnaire for the whole 
population, during each of the evaluation times, 
each 2 weeks after the study commencement. 
Evaluation showed no significant differential 
alterations in any of the items between the two 
groups. If the change in the overall Birmingham 
IBS symptom questionnaire scores were 
determined and compared to each other, despite 
the significant decrease in each of them, no 
differential significant difference in the rate 
of alterations in total questionnaire scores has 
been detected at the last follow up (-6.7±6.8 vs. 
-6.7±6.5 for the intervention and placebo groups, 
respectively; p=0.95).
n = 150 entered
5 left due to side effects
or symptom deterioration
n = 145
6 did not attend for the
final evaluation or did not
filled the final form
n=139
entered final analysis
Figure 1. Flowchart indicative of flow of the study participants 
during the study course
Table 1. Comparing demographic features of patients in 
the probiotic and placebo groups
Parameter Intervention Placebo 
Age (Year) 38.7±14.5 37.3±11.9
Weight (Kg) 69.4±15.1 74.1±51.6
Height (Cm) 169.3±9.2 165.9±21.9
Normal BMI* (%) 35 (53) 38 (55)
IBS** main 
symptom, n (%)
 - Diarrhea 22 (33) 27 (40)
 - Constipation 31 (46) 24 (36)
 - Both 14 (21) 16 (24)
*Calculated by the formula: Weight (Kg)/Height (m)2, 
**Irritable bowel syndrome
Because of potential confounding effects of 
some major factors associated with the disease 
or patients, we conducted re-analyses after 
stratifying the data for these factors in order to 
censor these perplexing effects from the original 
pharmaceutical authority:
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Reanalysis After Stratification for IBS Types
At the second step, the analysis was repeated 
after stratifying the data for the main IBS 
complaint (diarrhea vs. constipation) to evaluate 
potential effects of probiotic treatment on 
different IBS types. In the diarrhea-predominant 
IBS, probiotic therapy showed a significant 
improvement in the item 8 (Table 1) after 2 
weeks (-0.47±0.8 vs. -0.13±0.3; p=0.05) and 
6 weeks (-0.78±1.1 vs. -0.1±0.7, p=0.03) of 
probiotic therapy when they were compared to 
their counterparts on placebo. Also, probiotic 
therapy was significantly more effective than 
placebo in reducing the feeling of urgency 
(item 10, Table 1) in IBS patients with diarrhea-
predominant symptoms (-0.84±1.5 vs. -0.04±0.9; 
p=0.03). Nonetheless, none of the 11 evaluated 
items had changed significantly in patients with 
constipation-predominant IBS on probiotics 
versus those receiving placebo. In IBS patients 
with both diarrhea-constipation symptoms, 
probiotic therapy was associated with worse 
symptoms of item-5 (Table 1) after 4weeks 
(-0.4±0.7 vs. -1.1±0.8; p=0.035) and 6 weeks 
(-0.36±0.9 vs. -1.4±1.2; p=0.025), compared to 
placebo therapy.
Reanalysis After Stratification for BMI and 
IBS Type
Again, a reanalysis of the study results has 
been conducted after stratifying data for both 
IBS predominant symptoms and BMI. So, with 
three group in IBS-type and two in BMI grouping 
(BMI≤25 & BMI>25), we have six subgroups in 
which potential effects of probiotic therapy have 
been compared to that of placebo:1 Diarrhea-
predominant IBS and low-normal BMI: Item 
10 (Table 1) improved due to probiotic therapy 
at the first 2 weeks (-1±1.3 vs. 0±0.9; p=0.048); 
constipation-predominant IBS and low-normal 
BMI: Item 5 improved after 6 weeks in the 
case group compared to the placebo (-2.1±1.2 
vs. -0.78±1.1; p=0.017); constipation-diarrhea 
IBS &low-normal BMI: Item 5 experienced 
worsening after probiotic therapy (vs. placebo) 
after 4 weeks of treatment start (-0.29±0.5 vs. 
-0.89±1.3; 0.05); diarrhea-predominant IBS & 
high BMI: No differential change in the IBS 
symptoms has been observed in the case versus 
control patients; constipation-predominant IBS 
and high BMI: improvement in item 6 two weeks 
after treatment has been observed in the case 
group (-0.45±0.8 vs. 0.22±0.8; p=0.04); diarrhea-
Table 2. Improvement rates in Birmingham IBS Symptom Questionnaire during the study period
Questionnaire 
items
Week 2 Week 4 Week 6
Probiotic 
(%)
Placebo 
(%)
OR  
(95% CI)
Probiotic 
(%)
Placebo 
(%)
OR  
(95% CI)
Probiotic 
(%)
Placebo 
(%)
OR:95% 
CI
1 34 (59) 26 (43) .5 (.3-1.1) 28 (51) 30 (57) 1.3 (.6-2.7) 33 (68) 36 (68) 1.2  
(.5-2.7)
2 29 (50) 23 (38) .6 (.3-1.3) 26 (47) 29 (55) 1.3 (.6-2.9) 25 (48) 32 (60) 1.6  
(.8-3.6)
3 26 (45) 26 (43) .9 (.5-1.9) 24 (44) 27 (51) 1.3 (.6-2.9) 27 (52) 29 (55) 1.1  
(.5-2.4)
4 16 (28) 24 (40) 1.7  
(.8-3.8)
24 (44) 22 (41) .9 (.4-2) 28 (54) 23 (43)
.6  
(.3-1.4)
5 22 (38) 21 (35) .9 (.4-1.9) 26 (47) 31 (58) 1.6 (.7-3.4) 29 (56) 30 (57) 1 (.5-2.3)
6 22 (38) 15 (25) .5  
(0.2-1.2)
27 (49) 22 (41) .7 (.3-1.6) 26 (50) 21 (40) .7 (.3-1.4)
7 26 (45) 27 (45) 1 (.5-2.1) 27 (49) 28 (53) 1.2 (.5-2.5) 35 (67) 31 (58) .7 (.3-1.5)
8 19 (33) 15 (25) .7 (.3-1.5) 24 (44) 21 (40) .8 (.4-1.8) 22 (42) 20 (38) .9 (.4-1.9)
9 9 (15) 8 (13) .8 (.3-2.3) 8 (14) 11 (21) 1.5 (.6-4.2) 11 (21) 12 (23) 1.1  
(.4-2.8)
10 17 (29) 17 (28) 1 (.4-2.1) 22 (40) 24 (45) 1.2 (.6-2.7) 22 (42) 20 (38) .8 (.4-1.8)
11 22 (38) 15 (25) .5 (.2-1.2) 18 (33) 19 (36) 1.1 (.5-2.5) 19 (36) 23 (43) 1.3  
(.6-2.9)
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constipation IBS and high BMI: Worsening in 
items 2 (0.00±0.000 vs. -1.5±1.1; p=0.017) and 
4 (0.5±1.1 vs. -0.4±0.79; p=0.05) both after 6 
weeks of treatment were detected.
Reanalysis After Categorization of Symptom 
Changes of IBS
Unlike previous analyses on the absolute 
change in the scorings of the Birmingham 
questionnaire, we reanalyzed the data after 
categorizing the change as improvement and 
worsening of the scores for each, and then 
made crosstabs. As can be seen in Table 2, 
no significant change has been observed in 
the evaluated items in any of the time points. 
Stratification of data entering the IBS type into 
the crosstabulation did not change the results. 
DISCUSSION
Our study failed to demonstrate a broad 
therapeutic effect for probiotic therapy with 
E. coli Nissle 1917 in improving symptoms of 
patients with refractory IBS, in general. Although 
the efficacy of the probiotic E-coli Nissle 1917 
was to some degree and in some individual 
items superior to that of placebo, the significance 
level has rarely been achieved; and when the 
questionnaire’s scores have been categorized as 
improved and not improved, none of the analyses 
reached significance level.In fact, almost all of 
the questionnaire items in any of the follow-up 
time points have shown overall improvements; 
nonetheless these therapeutic effects were seen 
in both the case and control groups, with no 
significant difference in most cases. Interestingly, 
in some cases, the beneficial effect of placebo 
was shown to be even significantly better than 
the probiotic, which can be due to potential 
deleterious effects for the probiotic therapy in 
particular conditions which would be discussed 
latter. A number of explanations can be put 
forward for this observation. The scarcity of 
significance may be due to the limited sample 
size. Although compared to the literature of 
similar topic, our sample size seems comparable 
to the previous studies15 or quite larger.16 Another 
potential explanation can be the limited follow up 
time of 6 weeks, through which our patients have 
been observed. In the only published study about 
potential therapeutic effects of probiotic E. coli 
Nissle 1917 in IBS, the probiotic was minimally 
effective only 10 to 11 weeks after the therapy 
commencement.17
Literature suggests that E.coli Nissle 1917 
inhibits the visceral hypersensitivity associated 
with trinitrobenzenesulphonic acid (TNBS) 
colitis.18 Moreover, inhibitory effects have been 
observed for probiotic E. coli strain Nissle 1917 
on adhesion to and invasion of intestinal epithelial 
cells by adherent-invasive E. coli strains isolated 
from patients with Crohn’s disease, suggestive of 
its preventive or curative role in probiotic therapy 
of these patients.19,20 For the same reasons and 
due to its demonstrated beneficial effects in the 
clinical trials, E. coli Nissle 1917 is used in the 
management of inflammatory bowel syndrome 
in the clinical setting.21
Despite the lack of obtaining overall negative 
significant effect for probiotic therapy in this 
study compared to the placebo, in some of the 
time points and in individual items, significance 
level was achieved. Although one may put doubt 
on the credibility of the found relations, but 
one another may argue that specific probiotic 
therapy might only have some beneficial or even 
deleterious effects on some individual symptoms 
in particular conditions, including the IBS types. 
For example, we found differential effects for 
probiotic therapy in either diarrhea-predominant 
or constipation-predominant or mixed-symptom 
IBS; in diarrhea-predominant, both urgency and 
sleeping disturbances were significantly improved 
in two evaluation time points at 2 and 6 weeks 
after treatment commenced, while in constipation-
predominant IBS, no improvement in any of the 
evaluated factors has been detected. Nonetheless, 
in patients with diarrhea-constipation IBS, 
probiotic therapy was associated with deleterious 
effects in needing strain in passing stool in two 
time points, which may be considered confirmative 
to each other. So, according to these findings, we 
recommend IBS patients with mixed diarrhea-
constipation symptoms should avoid using 
probiotic E. coli Nissle 1917. Similar conclusions 
can be made in other founded significance levels 
in the results section.
Literature also presents contradictory 
results for the therapeutic value of probiotic 
therapy in IBS. A comprehensive systematic 
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review on different probiotic used in IBS by 
different trials concluded that only the probiotic 
Bifidobacteriuminfantis 35624 was associated 
with a significant efficacy.22 Another reason 
behind the controversial results about probiotic 
treatment in IBS patients is that IBS is not a 
single entity but rather aset of not well defined 
disorders.23 Therefore, the fact that there is no well 
known effective treatment for all these patients 
can also be explained. Evidence suggests that a 
given therapeutic approach in different patient 
populations corresponds to a large dissimilarity in 
the result (discussed above). In the current study, 
it was shown that even in the subpopulations of 
a unique study, profound disparities observed in 
the responses to treatment.While the probiotic 
E.coli Nissle 1917 was, though minimally, 
effective in diarrhea-predominant IBS, it was 
destructive in diarrhea-constipation mixed 
IBS symptomatology. So, maybe different 
presentations of IBS would, to some degree, 
reveal different pathogenesis, necessitating 
customization of treatment protocols for each 
specific type of IBS; in fact, several authors have 
already suggested this approach.24,25
There are several mechanisms proposed 
to explain therapeutic effects of probiotics 
in IBS. Through cross talk, quorum sensing 
systems, probiotics can alter microflora of 
the intestine directly; or indirectly through 
immunomodulatory, antiinflammatory and 
barrier activities.26 It has also been demonstrated 
that in IBS patients, persistent changes in 
proinflammatory (IL-12) and antiinflammatory 
(IL-10) cytokines occur27; in which probiotics 
have been shown to improve IL-12/IL-10 ratio 
concomitant to clinical improvement. More 
particularly about E.coli Nissle 1917, evidence 
suggests that it stimulates IL-10 production 
of peripheral mononuclear cells28, improves 
intestinal motility29, prevents the invasion of 
pathogens into the mucosa30, and induces the 
synthesis of antimicrobial peptides including 
human β-defensins and also synthesis of tight-
junction proteins in intestinal epithelial cells.31
CONCLUSION
Probiotic therapy with E.coli Nissle 1917 
was not able to induce significant improvement 
in the symptoms of patients with non-categorized 
IBS. Nevertheless, when IBS patients were 
recategorized to subgroups according to their 
main symptoms, evaluation of the efficacy of 
the probiotic on some individual items in the 
symptom list reached the significance level. 
However, due to some limitations of the current 
study including the limited sample size, and 
borderline p values achieved through analyses, 
prospective clinical trials are recommended for 
confirming our findings.
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